Evidence map›Paper›PMID 37073308›Full record

ArticleIn silico pharmacology2023

An insight into the mechanisms of action of selected bioactive compounds against epigenetic targets of prostate cancer: implications on histones modifications.

Babangida Sanusi Katsayal, Gilead Ebiegberi Forcados, Abdurrahman Pharmacy Yusuf, Yunus Aisha Lawal, Shehu Aisha Jibril, Hussaini Nuraddeen, Musa Mubarak Ibrahim, Idris Zubairu Sadiq, Murtala Bello Abubakar, Ibrahim Malami and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In silico pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Babangida Sanusi KatsayalDepartment of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Kaduna State Nigeria.
Gilead Ebiegberi ForcadosBiochemistry Division, National Veterinary Research Institute, Vom, Nigeria.
Abdurrahman Pharmacy YusufDepartment of Biochemistry, School of Life Sciences, Federal University of Technology, Minna, Niger State Nigeria.
Yunus Aisha LawalDepartment of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Kaduna State Nigeria.
Shehu Aisha JibrilDepartment of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Kaduna State Nigeria.
Hussaini NuraddeenDepartment of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Kaduna State Nigeria.
Musa Mubarak IbrahimDepartment of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Kaduna State Nigeria.
Idris Zubairu SadiqDepartment of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Kaduna State Nigeria.
Murtala Bello AbubakarDepartment of Physiology, Faculty of Basic Medical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria.
Ibrahim MalamiCentre for Advanced Medical Research & Training (CAMRET), Usmanu Danfodiyo University, Sokoto, Nigeria.
Ibrahim Babangida AbubakarDeparment of Biochemistry, Faculty of Life Sciences, Kebbi State University of Science and Technology Aliero, Aliero, Nigeria.
Aliyu MuhammadDepartment of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Kaduna State Nigeria.
Ahmadu Bello University · NGKebbi State University of Science and Technology · NGUsmanu Danfodiyo University · NGFederal University of Technology Minna · NGNational Veterinary Research Institute · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is a leading cause of morbidity and mortality among men globally. In this study, we employed an in silico approach to predict the possible mechanisms of action of selected novel compounds reported against prostate cancer epigenetic targets and their derivatives, exhausting through ADMET profiling, drug-likeness, and molecular docking analyses. The selected compounds: sulforaphane, silibinin, 3, 3'-diindolylmethane (DIM), and genistein largely conformed to ADMET and drug-likeness rules including Lipinski's. Docking studies revealed strong binding energy of sulforaphane with HDAC6 (- 4.2 kcal/ mol), DIM versus HDAC2 (- 5.2 kcal/mol), genistein versus HDAC6 (- 4.1 kcal/mol), and silibinin against HDAC1 (- 7.0 kcal/mol) coupled with improved binding affinities and biochemical stabilities after derivatization. Findings from this study may provide insight into the potential epigenetic reprogramming mechanisms of these compounds against prostate cancer and could pave the way toward more success in prostate cancer phytotherapy.

Indexed as

3, 3’-diindolylmethaneBioactive compoundsEpigeneticsGenisteinProstate cancerSilibininSulforaphane

Identifiers

PMID37073308
PMCPMC10105819
OpenAlexW4365813101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.